论文部分内容阅读
目的:探讨HE4(人类附睾蛋白4)、CA125在卵巢癌组织及血清中的表达及其临床意义。方法:选择2010年12月～2012年7月海南医学院附属医院收治的卵巢癌60例、良性卵巢肿瘤60例和正常卵巢组织35例,采用免疫组化法检测不同卵巢组织中的HE4和CA125的蛋白表达情况;应用酶联免疫吸附法检测术前、术后血清HE4及CA125的浓度,综合分析各参数之间的临床相关性。结果:HE4及CA125的蛋白表达卵巢癌组高于良性卵巢肿瘤组和正常卵巢组(P<0.000 1);HE4及CA125的血清水平卵巢癌组均高于良性卵巢肿瘤组和正常卵巢组(P<0.000 1)。血清HE4和CA125联合检测对卵巢癌的诊断敏感性均高于两者单项检测,为90%,特异性高于CA125单项检测,低于HE4单项检测。卵巢癌组术前血清CA125及HE4的表达水平明显高于术后,差异有统计学意义(P<0.000 1)。结论:HE4、CA125在卵巢癌组织中的蛋白表达与血清水平联合检测是卵巢癌早期诊断、疗效评价及预后评估的敏感综合指标,可为临床个性化防治提供科学实验依据。
Objective: To investigate the expression of HE4 (human epididymis protein 4) and CA125 in ovarian cancer tissues and serum and its clinical significance. Methods: 60 cases of ovarian cancer, 60 cases of benign ovarian tumor and 35 cases of normal ovarian tissue were collected from Affiliated Hospital of Hainan Medical College from December 2010 to July 2012. Immunohistochemistry was used to detect the expression of HE4 and CA125 in different ovarian tissues The protein levels of HE4 and CA125 in preoperative and postoperative serums were detected by enzyme-linked immunosorbent assay (ELISA). The clinical correlations among the parameters were analyzed. Results: The protein expressions of HE4 and CA125 in ovarian cancer group were higher than those in benign ovarian tumor group and normal ovary group (P <0.000 1). The serum levels of HE4 and CA125 in ovarian cancer group were significantly higher than those in benign ovarian tumor group and normal ovary group <0.000 1). Serum HE4 and CA125 combined detection of ovarian cancer diagnostic sensitivity were higher than the two single test, 90%, specificity higher than CA125 single test, lower than HE4 single test. Preoperative serum levels of CA125 and HE4 in ovarian cancer group were significantly higher than those in postoperative, the difference was statistically significant (P <0.000 1). Conclusion: The combined detection of HE4 and CA125 in ovarian cancer tissues and serum levels is a sensitive and comprehensive indicator of early diagnosis, evaluation of curative effect and prognosis evaluation of ovarian cancer. It can provide scientific basis for clinical personalized prevention and treatment.